{"id":"lcs12","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Musculoskeletal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PCSK9, LCS12 increases the levels of low-density lipoprotein (LDL) receptors on the liver surface, leading to reduced levels of LDL cholesterol in the blood.","oneSentence":"LCS12 is a small molecule that inhibits the PCSK9 enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:24.091Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT02146950","phase":"","title":"European Active Surveillance Study of LCS12","status":"ACTIVE_NOT_RECRUITING","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2014-06-17","conditions":"Contraception","enrollment":97265},{"nctId":"NCT01254292","phase":"PHASE3","title":"LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-01-06","conditions":"Contraception","enrollment":567},{"nctId":"NCT00528112","phase":"PHASE3","title":"Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-08","conditions":"Contraception","enrollment":2885},{"nctId":"NCT01397097","phase":"PHASE3","title":"LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-09","conditions":"Contraception","enrollment":766},{"nctId":"NCT01434160","phase":"PHASE3","title":"LCS12 Adolescent Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-09","conditions":"Contraception","enrollment":304},{"nctId":"NCT00185380","phase":"PHASE2","title":"Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-04","conditions":"Contraception","enrollment":742}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LCS12","genericName":"LCS12","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LCS12 is a small molecule that inhibits the PCSK9 enzyme. Used for Hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}